
Sign up to save your podcasts
Or


Although there have been significant advances in OAB treatments, OAB is significantly under-recognised and under-treated within the primary care setting. It is well established that there is a high “willingness to learn” about OAB management within primary care, and that educational activities can have a lasting impact on clinical practice. This episode will explore the motivation for primary care physicians to learn about OAB, the impact continuing education can have, and how trends in OAB management can impact how primary care physicians care for OAB patients.
Disclaimer:
This presentation include products/indications which may not be approved in your country. Physicians should take into account the patient’s individual circumstances and consult the approved product information before prescribing.
Astellas’ products availability, starting dose and indications may vary from country to country. These presentations are prepared solely for education of the healthcare professionals and does not necessarily reflect the opinions or recommendations of the sponsor.
Astellas prohibits the promotion of unapproved drug usage and complies with all applicable laws, regulations, and company policies.
Approval code: INT-M-BET-202107-24
By Astellas PharmaAlthough there have been significant advances in OAB treatments, OAB is significantly under-recognised and under-treated within the primary care setting. It is well established that there is a high “willingness to learn” about OAB management within primary care, and that educational activities can have a lasting impact on clinical practice. This episode will explore the motivation for primary care physicians to learn about OAB, the impact continuing education can have, and how trends in OAB management can impact how primary care physicians care for OAB patients.
Disclaimer:
This presentation include products/indications which may not be approved in your country. Physicians should take into account the patient’s individual circumstances and consult the approved product information before prescribing.
Astellas’ products availability, starting dose and indications may vary from country to country. These presentations are prepared solely for education of the healthcare professionals and does not necessarily reflect the opinions or recommendations of the sponsor.
Astellas prohibits the promotion of unapproved drug usage and complies with all applicable laws, regulations, and company policies.
Approval code: INT-M-BET-202107-24